Steve Abrams
Socio
As a member of the Global Life Sciences Leadership Team, Steve Abrams works with clients in many areas of the life sciences ecosystem, such as oncology therapies, pain products, dermatology therapies, vaccines, diagnostics, medical devices and drug/device combinations, orphan drugs, and gene therapies. He also counsels a variety of companies that provide services to the life sciences industry.
Steve has successfully negotiated and completed a range of life sciences transactions, with a particular focus on capital market offerings (IPOs, follow-on offerings, ATMs, RDOs, PIPES, and private placements), collaboration/licensing transactions, and M&A transactions. Additionally, he regularly advises public and privately held clients, including boards of directors, on securities, governance, transactional, and a range of other complex issues.
Steve is a member of the board of directors of inTEST Corporation (NASDAQ: INTT), and a member of its Audit and Compensation Committees. He is Chair of its Nominating Committee as well. Steve is also a member of the board of directors of the National Association of Corporate Directors - Philadelphia Chapter. He has lectured in front of various groups and published articles on securities, governance, and M&A issues.
Premios y reconocimientos
2017
Finance: Capital Markets: Equity Offerings
Legal 500 US
2018-2019
Life Sciences Star
LMG Life Sciences
Experiencia destacada
Represented a commercial-stage pharmaceutical company in US$100m and US$50m follow-on offerings led by Jefferies, Cowen, and Piper Jaffray.
Represented a commercial-stage pharmaceutical company on its US$70m follow-on offering and US$90m at-the-market offering.
Represented a clinical-stage pharmaceutical company on its US$50m at-the-market offering.
Represented an Australian-based clinical-stage pharmaceutical company on its US$40m private placement.
Represented a clinical-stage biotechnology company in US$40m and US$30m follow-on offerings and its US$35m at-the-market offering.
Represented a publicly traded biotechnology company in its US$63m sale.
Represented a publicly traded commercial-stage pharmaceutical company on an acquisition of a privately held specialty pharmaceutical company.
Represented a pre-clinical-stage pharmaceutical company in its US$48m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*
Represented a clinical-stage pharmaceutical company in its US$80m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*
Represented a NASDAQ Global Market developer and supplier of injectable drug delivery systems in a US$45m underwritten offering of common stock.*
Represented a clinical-stage biopharmaceutical company in its US$40m at-the-market equity program led by Cowen and Company.*
Represented a publicly traded clinical stage pharmaceutical company in a US$65.6m underwritten offering of common stock.*
Represented a provider of integrated clinical documentation solutions for the U.S. health care system in a US$130m acquisition.*
Represented a provider of integrated promotional outsource services to life sciences companies in its US$55m acquisition.*
Represented a specialty pharmaceutical company in its US$138m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.
Represented a specialty pharmaceutical company in its acquisition of a commercial-stage specialty pharmaceutical company and related equity and debt financing.
Represented a clinical-stage oncology company in its reverse merger into a NASDAQ-listed public company.
Represented a specialty pharmaceutical company in its co-promotional agreement with a major orthopaedic company.
Represented a commercial-stage specialty pharmaceutical company in its US$120m follow-on public offering through a syndicate of underwriters led by Jefferies and Piper Jaffray.
Represented Arbutus Biopharma Corporation on an at-the-market equity offering led by Jefferies.
*Asuntos desarrollados antes de su incorporación a Hogan Lovells.
